Zebrafish Inflammatory Disease Model and Anti-Inflammatory Screening Method
Summary
USPTO published patent application US20260107927A1, filed 2023-05-12 (Application No. 18879542), assigned to Raydel Korea Co., Ltd., inventor Kyung-Hyun Cho. The application claims zebrafish embryo and adult models constructed by inducing inflammation with carboxymethyllysine (CML), a glycation toxin, and a method for screening anti-inflammatory agents using these models. The invention reportedly enables prevention or treatment of inflammatory diseases through a more convenient and cost-effective screening approach.
“The present invention relates to zebrafish embryo and adult models constructed by inducing inflammation with carboxymethyllysine (CML), which causes glycation toxicity, and a method for screening anti-inflammatory agents using the same.”
About this source
USPTO classification A61K covers pharmaceutical preparations: formulations, dosage forms, combination therapies, delivery systems, and the vehicles that carry active ingredients. Every newly published application in A61K lands in this feed, around 245 a month. Applications publish 18 months after filing, so this feed reveals what pharma formulators at major sponsors and generics were working on in the prior year and a half. Watch this if you compete in drug formulation, file freedom-to-operate analyses, scout competitive drug products before clinical readouts, or follow novel delivery platforms like nanoparticles, lipid carriers, and long-acting injectables.
What changed
USPTO published patent application US20260107927A1, covering zebrafish embryo and adult inflammatory disease models induced by carboxymethyllysine (CML) and a method for screening anti-inflammatory agents. The application includes CPC classifications A01K 67/027, A61K 49/0008, and others covering zebrafish breeding, animal models, and therapeutic applications.
Affected parties in the pharmaceutical and biotechnology sectors should monitor this application's prosecution for potential freedom-to-operate implications in zebrafish-based anti-inflammatory drug discovery. Competitors developing similar glycation-toxicity or zebrafish-screening platforms may need to conduct prior art reviews to assess their own patent positions relative to these claims.
Archived snapshot
Apr 24, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
ZEBRAFISH ANIMAL MODEL FOR INFLAMMATORY DISEASES AND METHOD FOR SCREEING ANTI-INFLAMMATORY AGENTS USING SAME
Application US20260107927A1 Kind: A1 Apr 23, 2026
Assignee
RAYDEL KOREA CO., LTD.
Inventors
Kyung-Hyun Cho
Abstract
The present invention relates to zebrafish embryo and adult models constructed by inducing inflammation with carboxymethyllysine (CML), which causes glycation toxicity, and a method for screening anti-inflammatory agents using the same. The present invention provides a method for screening a novel anti-inflammatory agent using zebrafish in which embryonic death, acute cytokine storm, and neuro-paralysis has been induced, whereby inflammatory diseases can be prevented or treated in a more convenient and cost-effective manner.
CPC Classifications
A01K 67/027 A61K 49/0008 A01K 2207/20 A01K 2227/40 A01K 2267/0368
Filing Date
2023-05-12
Application No.
18879542
Parties
Related changes
Get daily alerts for USPTO Patent Applications - Pharma (A61K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Pharma (A61K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.